science
Rise in Testing of Unregulated Peptides in UK Amid Weight-Loss and Wellness Demand
Laboratories in the UK and internationally are processing thousands of samples of unregulated peptides sent by consumers for quality verification. These substances, often marketed for weight loss, biohacking, and anti-aging, include experimental compounds like retatrutide, which lack regulatory approval.
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Laboratories testing unregulated peptides have seen a sharp increase in submissions from the UK, driven by demand for injectable substances promoted for weight loss and wellness. Finnrick, a Texas-based lab, processes around 60,000 samples annually, including approximately 2,000 orders from the UK since 2024.
Janoshik Analytical in the Czech Republic handles 5,000 samples monthly, with the UK ranking third globally in testing volume alongside Canada. Peptides are short chains of amino acids, occurring naturally in the body as hormones like insulin and synthetically produced for various uses.
They form the basis of prescription drugs such as Wegovy, which contains semaglutide mimicking the GLP-1 hormone, and Mounjaro, which uses tirzepatide. Unregulated versions, including bootleg copies of these drugs and experimental compounds like retatrutide, are sold online for research purposes only but injected by users.
Quality issues persist in these products. Finnrick analysis shows about one-third of thousands of tested peptides fail checks for identity, purity below 98%, or incorrect quantity. The lab purchases samples through consumer channels and accepts public submissions since June 2023, flagging vendor-direct products on its site.
The peptide-testing industry expanded rapidly over the past three to four years, coinciding with the popularity of GLP-1 drugs. Peter Magic, chemist at Janoshik Analytical, attributed the surge to semaglutide, followed by tirzepatide and retatrutide, which remains in clinical trials and unapproved in the UK, making its sale illegal.
Vendors exploit a legal grey area by labeling products for research, avoiding medicine classification and oversight. Profit margins are high, with vials bought for $15 in China and resold for 10 times that amount, attracting unregulated suppliers. The UK market ties with performance-enhancing drug channels, sharing factories and distribution.
